Dacarbazine
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
Bleomycin
Mechlorethamine
Hodgkin Disease
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Antineoplastic Agents, Alkylating
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
Procarbazine
Antineoplastic Combined Chemotherapy Protocols
Doxorubicin
Nimustine
Antineoplastic agent especially effective against malignant brain tumors. The resistance which brain tumor cells acquire to the initial effectiveness of this drug can be partially overcome by the simultaneous use of membrane-modifying agents such as reserpine, calcium antagonists such as nicardipine or verapamil, or the calmodulin inhibitor, trifluoperazine. The drug has also been used in combination with other antineoplastic agents or with radiotherapy for the treatment of various neoplasms.
Carmustine
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Mesna
Interferon-alpha
One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways.
Combined Modality Therapy
Prednisone
O(6)-Methylguanine-DNA Methyltransferase
Disease-Free Survival
Treatment Outcome
Cisplatin
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Survival Analysis
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Tamoxifen
Neoplasm Metastasis
Sarcoma
Cyclophosphamide
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Drug Administration Schedule
Neoplasm Staging
Niacinamide
An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.
Etoposide
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Vindesine
Ifosfamide
DNA Modification Methylases
Enzymes that are part of the restriction-modification systems. They are responsible for producing a species-characteristic methylation pattern, on either adenine or cytosine residues, in a specific short base sequence in the host cell's own DNA. This methylated sequence will occur many times in the host-cell DNA and remain intact for the lifetime of the cell. Any DNA from another species which gains entry into a living cell and lacks the characteristic methylation pattern will be recognized by the restriction endonucleases of similar specificity and destroyed by cleavage. Most have been studied in bacterial systems, but a few have been found in eukaryotic organisms.
Organophosphorus Compounds
Survival Rate
Melanoma, Experimental
Kaplan-Meier Estimate
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Interleukin-2
Remission Induction
Disease Progression
Pheochromocytoma
A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298)
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. (1/1313)
The purpose of this study is to characterize the absorption, metabolism, and excretion of carbon 14-labeled temozolomide (14C-TMZ) administered p.o. to adult patients with advanced solid malignancies. On day 1 of cycle 1, six patients received a single oral 200-mg dose of 14C-TMZ (70.2 microCi). Whole blood, plasma, urine, and feces were collected from days 1-8 and on day 14 of cycle 1. Total radioactivity was measured in all samples. TMZ, 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC), and 4-amino-5-imidazole-carboxamide (AIC) concentrations were determined in plasma, and urine and plasma samples were profiled for metabolite/degradation products. Maximum TMZ plasma concentrations were achieved between 0.33 to 2 h (mean, 1.2 h), and half-life, apparent volume of distribution, and oral clearance values averaged 1.9 h, 17 liters/m2, and 104 ml/min/m2, respectively. A first-order absorption, one-compartment linear model, which included first-order formation of MTIC from TMZ and elimination of MTIC via degradation to AIC, and a peripheral distribution compartment for AIC, adequately described the plasma TMZ, MTIC, and AIC concentrations. MTIC systemic clearance was estimated to be 5384 ml/min/m2, and the half-life was calculated to be 2.5 min. Metabolite profiles of plasma at 1 and 4 h after treatment showed that 14C-derived radioactivity was primarily associated with TMZ, and a smaller amount was attributed to AIC. Profiles of urine samples from 0-24 h revealed that 14C-TMZ-derived urinary radioactivity was primarily associated with unchanged drug (5.6%), AIC (12%), or 3-methyl-2,3-dihydro-4-oxoimidazo[5,1-d]tetrazine-8-carboxyl ic acid (2.3%). The recovered radioactive dose (39%) was principally eliminated in the urine (38%), and a small amount (0.8%) was excreted in the feces. TMZ exhibits rapid oral absorption and high systemic availability. The primary elimination pathway for TMZ is by pH-dependent degradation to MTIC and further degradation to AIC. Incomplete recovery of radioactivity may be explained by the incorporation of AIC into nucleic acids. (+info)Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. (2/1313)
DNA-dependent protein kinase (DNA-PK) and poly(ADP-ribose) polymerase (PARP) are activated by DNA strand breaks and participate in DNA repair. We investigated the interactive effects of inhibitors of these enzymes [wortmannin (WM), which inhibits DNA-PK, and 8-hydroxy-2-methylquinazolin-4-one (NU1025), a PARP inhibitor] on cell survival and DNA double-strand break (DSB) and single-strand break (SSB) rejoining in Chinese hamster ovary-K1 cells following exposure to ionizing radiation (IR) or temozolomide. WM (20 microM) or NU1025 (300 microM) potentiated the cytotoxicity of IR with dose enhancement factors at 10% survival (DEF10) values of 4.5 +/- 0.6 and 1.7 +/- 0.2, respectively. When used in combination, a DEF10 of 7.8 +/- 1.5 was obtained. WM or NU1025 potentiated the cytotoxicity of temozolomide, and an additive effect on the DEF10 value was obtained with the combined inhibitors. Using the same inhibitor concentrations, their single and combined effects on DSB and SSB levels following IR were assessed by neutral and alkaline elution. Cells exposed to IR were post-incubated for 30 min to allow repair to occur. WM or NU1025 increased net DSB levels relative to IR alone (DSB levels of 1.29 +/- 0.04 and 1.20 +/- 0.05, respectively, compared with 1.01 +/- 0.03 for IR alone) and the combination had an additive effect. WM had no effect on SSB levels, either alone or in combination with NU1025. SSB levels were increased to 1.27 +/- 0.05 with NU1025 compared with IR alone, 1.02 +/- 0.04. The dose-dependent effects of the inhibitors on DSB levels showed that they were near maximal by 20 microM WM and 300 microM NU1025. DSB repair kinetics were studied. Both inhibitors increased net DSB levels over a 3 h time period; when they were combined, net DSB levels at 3 h were identical to DSB levels immediately post-IR. The combined use of DNA repair inhibitors may have therapeutic potential. (+info)Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. (3/1313)
PURPOSE: The combination of chemotherapy with immunotherapeutic agents such as interleukin-2 and interferon alfa-2b has been reported to provide improved treatment results in patients with metastatic melanoma, compared with the use of chemotherapy alone. We have performed a prospective randomized trial in patients with metastatic melanoma, comparing treatment with chemotherapy to treatment with chemoimmunotherapy. PATIENTS AND METHODS: One hundred two patients with metastatic melanoma were prospectively randomized to receive chemotherapy composed of tamoxifen, cisplatin, and dacarbazine or this same chemotherapy followed by interferon alfa-2b and interleukin-2. Objective responses, survival, and toxicity in the two groups were evaluated at a median potential follow-up of 42 months. RESULTS: In 52 patients randomized to receive chemotherapy, there were 14 objective responses (27%), including four complete responses. In 50 patients randomized to receive chemoimmunotherapy, there were 22 objective responses (44%) (P2 = .071), including three complete responses. In both treatment groups, the duration of partial responses was often short, and there was a trend toward a survival advantage for patients receiving chemotherapy alone (P2 = .052; median survival of 15.8 months compared with 10.7 months). Treatment-related toxicities were greater in patients receiving chemoimmunotherapy. CONCLUSION: With the treatment regimens used in this study, the addition of immunotherapy to combination chemotherapy increased toxicity but did not increase survival. The use of combination chemoimmunotherapy regimens is not recommended in the absence of well-designed, prospective, randomized protocols showing the benefit of this treatment strategy. (+info)Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. (4/1313)
PURPOSE: The primary objective of this clinical study was to assess the feasibility of administering recombinant interleukin-2 and recombinant interferon alfa-2a before and after combination cytotoxic chemotherapy. After encouraging initial responses, the study was expanded to further evaluate the therapeutic potential, clarify the toxicities of this regimen, and explore any associated immunologic changes. PATIENTS AND METHODS: Eighty-four patients with metastatic melanoma, including patients with brain metastases, were treated on this 6-week protocol. Patients received combination cisplatin (25 mg/m2/d) and dacarbazine (220 mg/m2/d) on days 1 through 3 and 22 through 24 plus carmustine (150 mg/m2) on day 1. Interleukin 2 (13.5 million IU/m2/d) and interferon alfa (6 MU/m2/d) were administered on days 4 through 8 and 17 through 21. RESULTS: Among 83 patients assessable for response, 12 complete and 34 partial responses were documented (55% response rate). The median time to disease progression was 7 months, the median survival from study entry was 12.2 months, and the median survival from diagnosis of metastatic disease was 15.5 months. Although patients were hospitalized to receive treatment, intensive care unit support generally was not needed. Dose-limiting toxicities were related to elevations in serum bilirubin and serum creatinine levels. No patient developed a grade 4 clinical toxicity. Treatment produced a skin depigmentation, which was associated with prolonged survival. CONCLUSION: A plateau in both the survival and time to progression curves beyond 2 years (15% of the patients) and a greater than 10% disease-free survival beyond 4 years indicate that there may be a long-term benefit for some patients. The limited toxicity of this regimen should permit its use in most oncology settings. A randomized trial of chemoimmunotherapy versus chemotherapy should be performed to establish the value of chemoimmunotherapy for melanoma. (+info)Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine. (5/1313)
Deficiency in genes involved in DNA mismatch repair increases susceptibility to cancer, particularly of the colorectal epithelium. Using Msh2 null mice, we demonstrate that this genetic defect renders normal intestinal epithelial cells susceptible to mutation in vivo at the Dlb-1 locus. Compared with wild-type mice, Msh2-deficient animals had higher basal levels of mutation and were more sensitive to the mutagenic effects of temozolomide. Experiments using Msh2-deficient cells in vitro suggest that an element of this effect is attributable to increased clonogenicity. Indeed, we show that Msh2 plays a role in the in vivo initiation of apoptosis after treatment with temozolomide, N-methyl-N'-nitro-N-nitrosoguanidine, and cisplatin. This was not influenced by the in vivo depletion of O6-alkylguanine-DNA-alkyltransferase after administration of O6-benzylguanine. By analyzing mice mutant for both Msh2 and p53, we found that the Msh2-dependent apoptotic response was primarily mediated through a p53-dependent pathway. Msh2 also was required to signal delayed p53-independent death. Taken together, these studies characterize an in vivo Msh2-dependent apoptotic response to methylating agents and raise the possibility that Msh2 deficiency may predispose to malignancy not only through failed repair of mismatch DNA lesions but also through the failure to engage apoptosis. (+info)Treatment of neoplastic meningitis with intrathecal temozolomide. (6/1313)
Neoplastic meningitis (NM) results from leptomeningeal dissemination of cancers arising within the central nervous system or metastasizing to the leptomeninges from systemic neoplasms. The inability to produce therapeutic drug levels intrathecally (i.t.) with systemic administration and the minimal efficacy of chemotherapeutic agents currently available for direct i.t. use limit therapy. Temozolomide [8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4([3H])-one] is a novel methylating agent with proven activity against intraparenchymal malignant gliomas (MGs). Insolubility of the standard formulation prevents its efficacious use as an i.t. agent, however. To overcome this obstacle, we have developed a unique microcrystalline formulation of temozolomide with greatly enhanced solubility. Treatment of athymic rats bearing subarachnoid MER- human MG xenografts with four doses of i.t. microcrystalline temozolomide over a 2-week period produced a 142% increase in median survival at individual doses of 2.2 micromol (P = 0.0073) and a >367% increase in median survival at individual doses of 6.8 micromol (P = 0.0015). At the higher dose tested, three of eight rats treated developed no neurological symptoms and had no evidence of residual tumor on histological examination after treatment. Use of this microcrystalline formulation in athymic rats bearing subarachnoid MER+ human MG xenografts increased median survival >132% (P < 0.0058) at both dose levels tested. Toxicity directly attributable to the i.t. administration of microcrystalline temozolomide was exhibited in the highest dose groups only and was limited to small patchy areas of focal demyelination involving <5% of spinal cord long tracks. (+info)DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents. (7/1313)
We have generated mice deficient in O6-methylguanine DNA methyltransferase activity encoded by the murine Mgmt gene using homologous recombination to delete the region encoding the Mgmt active site cysteine. Tissues from Mgmt null mice displayed very low O6-methylguanine DNA methyltransferase activity, suggesting that Mgmt constitutes the major, if not the only, O6-methylguanine DNA methyltransferase. Primary mouse embryo fibroblasts and bone marrow cells from Mgmt -/- mice were significantly more sensitive to the toxic effects of the chemotherapeutic alkylating agents 1,3-bis(2-chloroethyl)-1-nitrosourea, streptozotocin and temozolomide than those from Mgmt wild-type mice. As expected, Mgmt-deficient fibroblasts and bone marrow cells were not sensitive to UV light or to the crosslinking agent mitomycin C. In addition, the 50% lethal doses for Mgmt -/- mice were 2- to 10-fold lower than those for Mgmt +/+ mice for 1,3-bis(2chloroethyl)-1-nitrosourea, N-methyl-N-nitrosourea and streptozotocin; similar 50% lethal doses were observed for mitomycin C. Necropsies of both wild-type and Mgmt -/mice following drug treatment revealed histological evidence of significant ablation of hematopoietic tissues, but such ablation occurred at much lower doses for the Mgmt -/- mice. These results demonstrate the critical importance of O6-methylguanine DNA methyltransferase in protecting cells and animals against the toxic effects of alkylating agents used for cancer chemotherapy. (+info)A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. (8/1313)
Temozolomide (TMZ) is an oral imidazotetrazinone that is spontaneously converted to 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC) at physiological pH. MTIC methylates DNA at the O6 position of guanine, although this lesion may be repaired by the enzyme O6-alkylguanine-DNA alkyltransferase (AGAT). In this study, TMZ was combined with cisplatin (CDDP), because both agents have single-agent activity against melanoma and other tumor types. Additionally, CDDP has been shown to inactivate AGAT, and subtherapeutic concentrations of CDDP have been shown to increase the sensitivity of leukemic blasts to TMZ. This Phase I study sought to determine the toxicities, recommended dose, and pharmacological profile of the TMZ/CDDP combination. Patients were treated with oral TMZ daily for 5 consecutive days together with CDDP on day 1 (4 h after TMZ) every 4 weeks at the following TMZ (mg/m2/day)/CDDP (mg/m2) dose levels: 100/75, 150/75, 200/75, and 200/100. Plasma samples were obtained on days 1 and 2 to evaluate the pharmacokinetic parameters of TMZ alone and in combination with CDDP. Fifteen patients received a total of 44 courses of TMZ/CDDP. The principal toxicities of the regimen consisted of neutropenia, thrombocytopenia, nausea, and vomiting, which were intolerable in two of six new patients treated at the 200/100 mg/m2 dose level. Of five patients receiving 17 courses at the next lower dose level (200/75 mg/m2), none experienced dose-limiting toxicity. Antitumor activity was observed in patients with non-small cell lung cancer, squamous cell carcinoma of the tongue, and leiomyosarcoma of the uterus. Pharmacokinetic studies of TMZ revealed the following pertinent parameters (mean +/- SD): time to maximum plasma concentration (Tmax) = 1.1+/-0.6 h (day 1) and 1.7+/-0.9 h (day 2); elimination half-life (t1/2) = 1.74+/-0.22 h (day 1) and 2.35+/-0.70 h (day 2); and clearance (Cl(s)/F) = 115+/-27 ml/min/m2 (day 1) and 141+/-109 ml/min/m2 (day 2). TMZ drug exposure, described by the area under the plasma concentration-time curve (AUCinfinity) and the maximum plasma concentration (Cmax), was similar on days 1 and 2. On the basis of these results, the recommended doses for Phase II clinical trials are TMZ 200 mg/m2/day for 5 days with 75 mg/m2 CDDP on day 1, every 4 weeks. The addition of CDDP did not affect the tolerable dose of single-agent TMZ (200 mg/m2/day x 5 days), nor did it substantially alter the pharmacokinetic behavior of TMZ. (+info)
Dacarbazine depletes the ovarian reserve in mice and depletion is enhanced with age<...
Inhibition of STAT3 reverses drug resistance acquired in temozolomide-resistant human glioma cells<...
Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme - Full Text View -...
Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma | Molecular Cancer Research
Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma | Molecular Cancer Research
Dacarbazine induces genotoxic and cytotoxic germ cell damage with concomitant decrease in testosterone and increase in lactate...
Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma - Tabular View -...
Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. - The Christie...
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma<...
Plus it
Brentuximab Vedotin Plus Dacarbazine or Bendamustine: New Options for Older Patients with Hodgkin Lymphoma? - ASH Clinical News
Final results of the TEMAVIR ANOCEF study in patients with unresectable glioblastoma | ESMO
Injection Dacarbazine Supplier,Exporter,Wholesaler,Distributor,Manufacturer in India
Pesquisa | Portal Regional da BVS
Resveratrol abrogates the Temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the Temozolomide-induced...
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in...
A Randomized, Placebo Controlled Phase IIb/III Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in...
Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma | HKMJ
An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo for Newly Diagnosed...
Rare Cancer News & Clinical Trials » Trial - CNS Tumor » An Investigational Immuno-therapy Study of Temozolomide Plus Radiation...
Plus it
Augmented HR repair mediates acquired temozolomide resistance in glioblastoma - Fingerprint
- University of Texas...
Efficacy of Novel Compound in Temozolomide-Resistant Brain Tumor Cell Lines in Mice | Penn State Hershey Neuro Report
Temozolomide : usage, side effects, expert advice and temozolomide based medicines | 1mg
Epigenetic characterisation of the 06 methyl-guanine DNA-methyltransferase promoter in New Zealand melanoma cell lines : a...
Phase II Portion of Trial of Dasatinib (Sprycel) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients...
Dacarbazine | Chemotherapy drugs - Macmillan Cancer Support
Click to print
Plus it
Dacarbazine | Harvard Catalyst Profiles | Harvard Catalyst
Dacarbazine Side Effects
Dr. George Demetri on the Mutagenic Properties and Future Potentials of Dacarbazine
Dacarbazine Dosage
Celdaz Dacarbazine 200mg Injection - Manufacturer, Supplier, Exporter
Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes - Zurich Open...
Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients...
Survival Benefits of Front-Line Treatment With Nivolumab for Advanced Melanoma Confirmed, Yet Questions Remain - The ASCO Post
Drug approved as part of frontline therapy for HL | MDedge Hematology and Oncology
DACLIZUMAb, Dacarbazine, DACARBAZINE, Dabrafenib, Dabigatran, D4T, Online Medical Diagnosis and Drugs Catalog
Institute of Cancer Research Repository - A Phase I/II study of lomustine and temozolomide in patients with cerebral...
Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo.
A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal...
Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report |...
18th World Congress of Basic and Clinical Pharmacology
A single cycle of treatment with temozolomide, alone or combined with O6-benzylguanine, induces strong chemoresistance in...
ANAVEX 7-1037 Reduces Rate of Cancer Tumor Growth 69% in Pre-Clinical Studies, Compared to Currently Marketed Drug Dacarbazine...
Inhibition of Dacarbazine on Melanoma Stem Cells
Novocure™ Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide in Combination with Optune®...
Ibudilast Plus Temozolomide Shows Preclinical Promise in Glioblastoma | Cancer Network
Plus it
Targeting the Akt-pathway to improve radiosensitivity in glioblastoma
5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (dtic, Dic, nsc- - by S K. Carter and M A. Friedman
Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide.
Clinical trials of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) given intravenously in the treatment of...
Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma...
The discovery that BRAF is a driver oncogene in cancer, and - Inhibitors of HDM2 and HDMX Binding to p53
Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. - PubMed - NCBI
Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed...
IDH1 Gene and ATRX Gene Prognostic in Anaplastic Astrocytoma | Personalized Medicine in Oncology
Plus it
Menin represses malignant phenotypes of melanoma through regulating multiple pathways - Gao - 2011 - Journal of Cellular and...
A novel treatment modality added to standard chemo- and radiotherapy in newly diagnosed glioblastoma-First report of the full...
GBM Treatment: One Small Step at a Time - Green Bay Oncology
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or...
Alfa Aesarâ„¢ 2-Bromo-1-(cyanomethyl)imidazole-4,5-dicarbonitrile, 97% 250mg Alfa Aesarâ„¢ 2-Bromo-1-(cyanomethyl)imidazole-4,5...
Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems - MalignantNoMore
Long-Term Data Show Optune Offers a Survival Benefit in Glioblastoma
Clinical Trial | RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis. -...
MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis. - Wellcome...
Clinical Trial | Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent
Low-Grade and Anaplastic Supratentorial, Infratentorial...
Triazenes
"Dacarbazine". The American Society of Health-System Pharmacists. Archived from the original on 11 September 2017. Retrieved 8 ...
Chemotherapy
Tetrazines include dacarbazine, mitozolomide and temozolomide. Aziridines include thiotepa, mytomycin and diaziquone (AZQ). ...
Melanoma
Chemotherapy drugs such as Dacarbazine have been the backbone of metastatic melanoma treatment since FDA approval in 1975 ... In June 2011, a clinical trial of ipilimumab plus dacarbazine combined this immune system booster with the standard ... June 2011). "Ipilimumab plus dacarbazine for previously untreated metastatic melanoma". The New England Journal of Medicine. ...
Melanoma
June 2011). "Ipilimumab plus dacarbazine for previously untreated metastatic melanoma". N. Engl. J. Med. 364 (26): 2517-26. doi ... In June 2011, a clinical trial of ipilimumab plus dacarbazine combined this immune system booster with the standard ... Chemotherapy drugs such as Dacarbazine have been the backbone of metastatic melanoma treatment since FDA approval in 1975 ...
ABVD
Dacarbazine).aspx DeVita V, Simon R, Hubbard S, Young R, Berard C, Moxley J, Frei E, Carbone P, Canellos G (1980). "Curability ... dacarbazine regimen?". J Clin Oncol. 22 (8): 1532-3. doi:10.1200/JCO.2004.99.010. PMID 15084636. van Leeuwen F, Klokman W, Veer ... vinblastine and dacarbazine (ABVD) chemotherapy in the adult human ovary". Human Reproduction. doi:10.1093/humrep/dew260. PMID ...
Pheochromocytoma
October 2008). "Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: ... and dacarbazine, collectively known as CVD. Response to therapy is measured by a reduction in total tumor volume as well as ... and dacarbazine". Annals of Internal Medicine. 109 (4): 267-73. doi:10.7326/0003-4819-109-4-267. PMID 3395037. Huang H, Abraham ... and dacarbazine chemotherapy". The Journal of Clinical Endocrinology and Metabolism. 94 (8): 2850-6. doi:10.1210/jc.2008-2697. ...
Arabinopyranosyl-N-methyl-N-nitrosourea
Gershanovich ML, Akimov MA (2004). "[Chemoimmunotherapy with dacarbazine and aranose combined with interferon-alpha in ... together with dacarbazine and interferon-alpha in combination chemotherapy. During preclinical trials it also shown some ...
Budd-Chiari syndrome
Other risk factors include the antiphospholipid syndrome, aspergillosis, Behçet's disease, dacarbazine, pregnancy, and trauma.[ ...
Fotemustine
A study has shown that fotemustine produces improved response rates and but does not increase survival (over dacarbazine in the ... "Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study". Journal of Clinical ...
Temozolomide
... is contraindicated in people with hypersensitivity to it or to the similar drug dacarbazine. The use of ... MTIC, the active metabolite AIC (part of the naturally occurring AICA ribonucleotide) The related drug dacarbazine for ...
Adjuvant therapy
Dacarbazine, temozolomide, and cisplatin all have a reproducible 10-20% response rate in metastatic melanoma.[citation needed ...
Genta (company)
"Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group". ... dacarbazine) with or without Genasense. The initial size of this trial was expanded to enable a direct comparison of safety and ...
Neuroblastoma RAS viral oncogene homolog
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma ...
Trabectedin
... Superior to Dacarbazine for Leiomyosarcoma, Liposarcoma FDA Approves Trabectedin (Yondelis) for Advanced Soft- ... after a phase III study comparing trabectedin with dacarbazine), the US FDA approved trabectedin (Yondelis) for the treatment ...
Vemurafenib
A phase III trial (vs dacarbazine) in patients with previously untreated metastatic melanoma showed an improved rates of ...
Immune-related response criteria
... or dacarbazine [DTIC]) in patients with advanced melanoma". Journal of Clinical Oncology. 26 (15_suppl): LBA9011. doi:10.1200/ ...
Tremelimumab
... or dacarbazine [DTIC]) in patients with advanced melanoma". Journal of Clinical Oncology. 26 (15S): LBA9011. doi:10.1200/jco. ...
DNA repair
April 2013). "Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a ...
Neoplasm
"Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II ...
Selumetinib
In the 152-patient trial, a combination of selumetinib and dacarbazine failed to improve progression-free survival compared ...
O-6-methylguanine-DNA methyltransferase
"Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II ...
Imidasool - Vikipeedia
Sellised ühendid on stabiilsemad kui näiteks Dacarbazine, mis on üks põhilisi nahavähi ravimeid. Imidasooli derivaatide hea ...
Binimetinib
"Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma" at ... binimetinib had a median progression-free survival of 2.8 months versus 1.5 months for those on the standard dacarbazine ...
Sunburn
Common drugs that may cause a phototoxic reaction include amiodarone, dacarbazine, fluoroquinolones, 5-fluorouracil, furosemide ...
BRAF (gene)
... dacarbazine. In clinical trials, B-Raf increased metastatic melanoma patient chance of survival. In spite of the drug's high ...
Eribulin
... compared to 8.4 months for participants treated with dacarbazine. Serious side effects may include a decrease in white blood ...
Somatostatinoma
... dacarbazine, doxorubicin or by 'watchful waiting' and surgical debulking via Whipple procedure and other resections of the ...
Doxorubicin
... dacarbazine), BEACOPP, CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone) and FAC (5-fluorouracil, ...
Brentuximab vedotin
... and dacarbazine) versus A+AVD (a combination of brentuximab vedotin plus AVD, or doxorubicin, vinblastine, and dacarbazine) for ... dacarbazine (AVD) chemotherapy as a firstline treatment for advanced classical Hodgkin lymphoma. Brentuximab vedotin was ...
List of MeSH codes (D03)
... dacarbazine MeSH D03.383.129.308.245 - dexmedetomidine MeSH D03.383.129.308.250 - econazole MeSH D03.383.129.308.253 - ...
Dacarbazine - Wikipedia
"Dacarbazine". International Drug Price Indicator Guide. Retrieved 8 December 2016.. *^ British national formulary : BNF 69 (69 ... Dacarbazine (DTIC), also known as imidazole carboxamide, is a chemotherapy medication used in the treatment of melanoma and ... As of mid-2006, dacarbazine is commonly used as a single agent in the treatment of metastatic melanoma,[5][6] and as part of ... Dacarbazine works by methylating guanine at the O-6 and N-7 positions.[14] Guanine is one of the four nucleotides that makes up ...
Dacarbazine: MedlinePlus Drug Information
Dacarbazine: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Dacarbazine is used to treat melanoma (a type of skin cancer) that has spread to other parts of your body. Dacarbazine is also ... Before receiving dacarbazine,. *tell your doctor and pharmacist if you are allergic to dacarbazine, any other medications, or ... When dacarbazine is used to treat melanoma, it may be injected once a day for 10 days in a row every 4 weeks or it may be ...
Dacarbazine News, Research
Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma Janssen Research & Development, LLC announced ... AstraZeneca today announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of ... The study met its primary endpoint of improving progression-free survival (PFS) compared with dacarbazine treatment. ... vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan. ...
Dacarbazine | Chemotherapy drugs - Macmillan Cancer Support
Dacarbazine (or DTIC), is a chemotherapy drug used to treat Hodgkin lymphoma, melanoma and soft tissue sarcoma. It may also be ... What is dacarbazine (DTIC)?. Dacarbazine (DTIC) is used to treat melanoma, Hodgkin lymphoma and soft tissue sarcoma. It may ... How dacarbazine is given. You will be given dacarbazine in the chemotherapy day unit or during a stay in hospital. A ... Less common side effects of dacarbazine. Flu-like symptoms. Dacarbazine may cause flu-like symptoms such as having a headache ...
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
... in combination with dacarbazine, as compared with dacarbazine plus placebo, improved overall survival in patients with ... Conclusions: Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dacarbazine plus ... plus dacarbazine (850 mg per square meter of body-surface area) or dacarbazine (850 mg per square meter) plus placebo, given at ... of patients treated with ipilimumab plus dacarbazine, as compared with 27.5% treated with dacarbazine and placebo (P,0.001). No ...
Dacarbazine Lyophilisate For Solution For Injection 100Mg Drug Medication Dosage Information
Bevacizumab vs Dacarbazine in Metastatic Melanoma - Full Text View - ClinicalTrials.gov
Bevacizumab vs Dacarbazine in Metastatic Melanoma. This study has been terminated. (Lack of financing of the study drug. Not ... Drug Information available for: Propranolol Dacarbazine Enalapril Enalapril maleate Enalaprilat Bevacizumab Genetic and Rare ... A Randomized Phase II Trial Comparing Bevacizumab Monotherapy With Dacarbazine (DTIC) in Treatment of Malignant Melanoma, ... Active Comparator: Dacarbazine Dacarbazine 1000mg/m2 q3w. Drug: Dacarbazine dacarbazine 1000 mg/m2 q3w ...
DBL Dacarbazine for Injection (Powder for injection) - myDr.com.au
DBL Dacarbazine for Injection (Powder for injection) - Consumer Medicines Information leaflets of prescription and over-the- ... You must not be given DBLâ„¢ Dacarbazine for Injection if you have an allergy to dacarbazine or any of the ingredients listed at ... Tell your doctor or dentist if you intend having any dental work while being treated with dacarbazine. Dacarbazine may increase ... You should not be given DBLâ„¢ Dacarbazine for Injection if you are breast-feeding. It is not known whether dacarbazine passes ...
Dacarbazine (DTIC, DIC, imidazole carboxamide) | Children's Education Materials
Dacarbazine (DTIC, DIC, imidazole carboxamide). Article Translations: (Spanish). How does this medicine work?. Dacarbazine (da- ... Blood counts begin to drop 3 to 7 days after dacarbazine is given and may be at their lowest 2 to 4 weeks after therapy. Blood ... Dacarbazine is given into the vein (IV) in the hospital or clinic. ... Sucking on hard candy while receiving dacarbazine may reduce an unpleasant taste. ...
Dacarbazine | Harvard Catalyst Profiles | Harvard Catalyst
"Dacarbazine" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical Subject ... This graph shows the total number of publications written about "Dacarbazine" by people in Harvard Catalyst Profiles by year, ... Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. Blood. ... Below are the most recent publications written about "Dacarbazine" by people in Profiles. ...
DBL Dacarbazine for Injection (Powder for injection)
... is a brand of medicine containing the active ingredient Dacarbazine. Find out about side effects, who ca... ... How DBLâ„¢ Dacarbazine for Injection is given. How much is given. Your doctor will decide what dose of dacarbazine you will ... DBLâ„¢ Dacarbazine for Injection is available only with a doctors prescription.. Before you are given DBLâ„¢ Dacarbazine for ... What DBLâ„¢ Dacarbazine for Injection is used for. Dacarbazine belongs to a group of medicines known as antineoplastic or ...
Dacarbazine, DTIC injection - AHealthyMe - Blue Cross Blue Shield of Massachusetts
Targeted Therapies Compared to Dacarbazine for Treatment of BRAFV600E Metastatic Melanoma: A Cost-Effectiveness Analysis
Dacarbazine was used as the comparator drug in both Phase III pivotal trials. Since patient characteristics of the dacarbazine ... and dacarbazine [32]. They found an ICER for vemurafenib compared to dacarbazine of $353,993/QALY, which is comparable to our ... median age 53 years) or dacarbazine (. , median age 50 years) and had a median time on study of 4.9 months. In both trials, ... and tenfold more expensive than dacarbazine even when including a prophylactic antiemetic regimen with dacarbazine. However, we ...
Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma - Tabular View - ClinicalTrials.gov
... inserted into a large vein under the skin of the chest or through a vein in the arm to receive dacarbazine. Dacarbazine will be ... inserted into a large vein under the skin of the chest or through a vein in the arm to receive dacarbazine. Dacarbazine will be ... Dacarbazine starting Dose 250 mg/m^2 a day on Days 1-3 of 21 Day Cycle. Imatinib starting Dose 400 mg a day on Days 1-21 of 21 ... Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma. The safety and scientific validity of ...
Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma - Full Text View -...
Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma (SICOG 0109). The safety and ... Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma: Phase III Study. ... Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant ... Drug Information available for: Dacarbazine Interferon Genetic and Rare Diseases Information Center resources: Neuroendocrine ...
A Phase I/II Study of Sunitinib and Dacarbazine
This is a combination Phase I/II design that explores the toxicity and activity of Sunitinib and Dacarbazine (DTIC) for ... A Phase I/II Study of Sunitinib and Dacarbazine in Patients With Metastatic Melanoma. Trial Phase:. Phase 1/Phase 2. Minimum ... combination of sunitinib and Dacarbazine (DTIC) for metastatic melanoma. Screening tests. (pre-study) will consist of a history ... A Phase I/II Study of Sunitinib and Dacarbazine in Patients With Metastatic Melanoma ...
Dacarbazine (CAS 4342-03-4) Market Research Report 2018
Market Research Report 2018 aims at providing comprehensive data on dacarbazine market globally and regionally (Europe, ... Dacarbazine prices in North America. 6.4. Dacarbazine prices in other regions. 7. DACARBAZINE END-USE SECTOR 7.1. Dacarbazine ... Dacarbazine market forecast. 6. DACARBAZINE MARKET PRICES. 6.1. Dacarbazine prices in Europe. 6.2. Dacarbazine prices in Asia ... Dacarbazine application spheres, downstream products. 3. DACARBAZINE MANUFACTURING METHODS. 4. DACARBAZINE PATENTS. Abstract. ...
Dacarbazine adverse effects - Answers on HealthTap
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That...
Drug: Cabozantinib S-malate Drug: Dacarbazine Other: Laboratory Biomarker Analysis Drug: Temozolomide Phase 2 ... Drugs used in chemotherapy, such as temozolomide and dacarbazine, work in different ways to stop the growth of tumor cells, ... If temozolomide is not available, patients receive dacarbazine IV over 15-60 minutes on day 1. Courses repeat every 21 days in ... Dacarbazine. Imidazole. Antineoplastic Agents, Alkylating. Alkylating Agents. Molecular Mechanisms of Pharmacological Action. ...
A peptide-modified solid lipid nanoparticle formulation of paclitaxel modulates immunity and outperforms dacarbazine in a...
A peptide-modified solid lipid nanoparticle formulation of paclitaxel modulates immunity and outperforms dacarbazine in a ... A peptide-modified solid lipid nanoparticle formulation of paclitaxel modulates immunity and outperforms dacarbazine in a ... PSM exerts more apoptotic and anti-invasive effects in B16F10 mice melanoma cells as compared to dacarbazine (DTIC), an ...
Inhibition of Dacarbazine on Melanoma Stem Cells
Inhibitory Effects and Mechanism analysis on the Inhibition of Dacarbazine on Melanoma Stem Cells Proliferation in vitro ... Inhibition of Dacarbazine on Melanoma Stem Cells. Info: 3256 words (13 pages) Essay. Published: 14th May 2018 in Biology ... Dacarbazine (DTIC), which can be used in a variety of cancers including fibrosarcoma [4], Hodgkins disease [5], lung cancer [6 ... Key words: melanoma; dacarbazine; microRNA; stem cell Introduction Melanoma is a kind of malignant tumor with an increasing ...
Effects of interferon-[alpha], verapamil and dacarbazine in the treatment of advanced malignant melanoma
57-Early stage ABVD (DOXOrubicin bleomycin VinBLASTine dacarbazine) | eviQ
Reduced efficacy of dacarbazine possible due to inhibition of the conversion of dacarbazine to its active metabolite (which may ... Increased toxicity of dacarbazine metabolite possible due to hastened and/or higher percentage of dacarbazine activation. Avoid ... Dacarbazine: TGA approved but not PBS reimbursed. Cost:. ~ $550 per cycle "How this cost is calculated" The cost displayed on ... Dacarbazine: TGA approved but not PBS reimbursed. Cost:. ~ $550 per cycle "How this cost is calculated" The cost displayed on ...
PRIME PubMed | Reduction of Dacarbazine cytogenetic effects on somatic cells in male mice using bee glue (Propolis) to manifest...
PubMed journal article Reduction of Dacarbazine cytogenetic effects on somatic cells in male mice using bee glue (Propolis) to ... and Dacarbazine-treated group (treated with 3.5mg/kg Dacarbazine). The fourth, fifth, and sixth were treated with Dacarbazine ... and Dacarbazine-treated group (treated with 3.5mg/kg Dacarbazine). The fourth, fifth, and sixth were treated with Dacarbazine ... Reduction of Dacarbazine cytogenetic effects on somatic cells in male mice using bee glue (Propolis) to manifest the scientific ...
Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients...
Dabrafenib Dacarbazine Dacogen® Dactinomycin Daratumumab Darbepoetin Alfa Darzalex® Dasatinib Daunorubicin Daunorubicin and ... Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients ... Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients ...
Abstract 2764: Effect of PNT2258 combinations with docetaxel, dacarbazine, or vemurafenib on the A375 melanoma xenograft |...
Dacarbazine alone was ineffective at 80 mg/kg/dose IP. Combination therapy was not superior to PNT2258 alone. In contrast, ... Abstract 2764: Effect of PNT2258 combinations with docetaxel, dacarbazine, or vemurafenib on the A375 melanoma xenograft. Wendi ... Overall, 1) PNT2258+docetaxel produced a greater than additive effect compared to single agents, 2) PNT2258+dacarbazine was not ... Abstract 2764: Effect of PNT2258 combinations with docetaxel, dacarbazine, or vemurafenib on the A375 melanoma xenograft ...
A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine
A Phase I, Open Label, Study of the Safety and Tolerability of KU-0059436 and Dacarbazine in the Treatment of Patients With ... A Phase I, Open Label, Study of the Safety and Tolerability of KU-0059436 and Dacarbazine in the Treatment of Patients With ... To determine the safety, tolerability, dose-limiting toxicity (DLT), and (MTD) of KU-0059436 in combination with dacarbazine. ...
Dacarbazine toxicity in murine liver cells: a model of hepatic endothelial injury and glutathione defense. | Journal of...
Dacarbazine toxicity in murine liver cells: a model of hepatic endothelial injury and glutathione defense.. L D Deleve ... Dacarbazine toxicity in murine liver cells: a model of hepatic endothelial injury and glutathione defense.. L D Deleve ... Dacarbazine toxicity in murine liver cells: a model of hepatic endothelial injury and glutathione defense.. L D Deleve ... Dacarbazine (5-(3,3-dimethyl-triazeno) imidazole-4-carboxamide), 3 and 6 mM, was toxic to SECs but not to hepatocytes. Onset of ...
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma ...
Background: The role of bleomycin and dacarbazine in the ABVD regimen (ie, doxorubicin, bleomycin, vinblastine, and dacarbazine ... Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkins lymphoma ... Interpretation: Dacarbazine cannot be omitted from ABVD without a substantial loss of efficacy. With respect to our predefined ... We aimed to investigate whether omission of either bleomycin or dacarbazine, or both, from ABVD reduced the efficacy of this ...
Metastatic melanomaDoxorubicinDTIC-DomePlus dacarbazineMalignant MelanomaVersus DacarbazineDosageABVDVialImidazole carboxamideIntravenousPrecautionsSingle agent dacarbazineReceived dacarbazine injectionStarting dacarbazine treatmentHodgkin'sIngredientsTreatmentDocetaxelCarboxamideCisplatinEffects of dacarbazineShown that dacarbazineAddition of dacarbazineToxicityDoseHepaticAntineoplasticGiven dacarbazineReceive dacarbazineSupplierRegimenDrugsIntravenouslyAbstractAllergicTreat melanomaChemotherapeuticChemotherapy drugEfficacyNauseaCombinationPhaseImpurityAlkylating AgentMelanoma therapyBelongs to the groupBody'sHospira
Metastatic melanoma13
- We conducted a phase 3 study of ipilimumab (10 mg per kilogram) plus dacarbazine in patients with previously untreated metastatic melanoma. (nih.gov)
- We randomly assigned 502 patients with previously untreated metastatic melanoma, in a 1:1 ratio, to ipilimumab (10 mg per kilogram) plus dacarbazine (850 mg per square meter of body-surface area) or dacarbazine (850 mg per square meter) plus placebo, given at weeks 1, 4, 7, and 10, followed by dacarbazine alone every 3 weeks through week 22. (nih.gov)
- Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dacarbazine plus placebo, improved overall survival in patients with previously untreated metastatic melanoma. (nih.gov)
- Until 2011, dacarbazine, a chemotherapeutic alkylating agent, was the standard of care for patients with metastatic melanoma despite its lack of survival benefit [ 7 , 8 ]. (hindawi.com)
- This is a combination Phase I/II design that explores the toxicity and activity of a combination of sunitinib and Dacarbazine (DTIC) for metastatic melanoma. (knowcancer.com)
- In this study, safety and clinical activity of L19-IL2 in combination with dacarbazine were assessed in patients with metastatic melanoma. (aacrjournals.org)
- The repeated administration of L19-IL2 in combination with dacarbazine is safe and shows encouraging signs of clinical activity in patients with metastatic melanoma. (aacrjournals.org)
- This article presents clinical evidence that the combination of dacarbazine with the tumor-targeting immunocytokine L19-IL2 (a biopharmaceutical consisting of the human recombinant antibody L19, specific to the alternatively spliced EDB domain of fibronectin, fused to human interleukin-2) is well tolerated in patients with metastatic melanoma and can induce long-lasting objective responses in a subset of patients. (aacrjournals.org)
- Despite such modest efficacy, dacarbazine still represents the reference treatment of metastatic melanoma, chosen as comparative arm in many clinical trials ( 8 ). (aacrjournals.org)
- Conclusion: Extended schedule escalated dose Temozolomide (7 days on 7 days off) is feasible and has an acceptable safety profile, but does not improve OS and PFS in metastatic melanoma when compared to standard dose dacarbazine. (eur.nl)
- Sorafenib-dacarbazine combination shows activity in metastatic melanoma. (northwestern.edu)
- Materials and methods: Peripheral blood lymphocytes from patients with metastatic melanoma undergoing dacarbazine chemotherapy every 21 days for a total of 7 cycles, were analysed for the presence of micronuclei with the CREST antikinetochore antibody technique. (elsevier.com)
- Luikart, SD & Kirkwood, JM 1982, ' A comparison of vinblastine/bleomycin/Cis-platin (VBD) with dacarbazine (DTIC) in metastatic melanoma ', Proceedings of the American Society of Clinical Oncology , vol. (umn.edu)
Doxorubicin9
- Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan. (news-medical.net)
- Recently published results of a phase 2 clinical trial have shown the best outcomes to date for newly diagnosed older Hodgkin lymphoma patients treated with brentuximab vedotin given before and after doxorubicin, vinblastine and dacarbazine chemotherapy, which is the standard of care. (news-medical.net)
- Background: The role of bleomycin and dacarbazine in the ABVD regimen (ie, doxorubicin, bleomycin, vinblastine, and dacarbazine) has been questioned, especially for treatment of early-stage favourable Hodgkin's lymphoma, because of the drugs' toxicity. (mdc-berlin.de)
- We prospectively compared adjuvant doxorubicin and dacarbazine (ADTIC) to a traditional doxorubicin and cyclophosphamide (AC) treatment, aiming at determining safety and assessing whether this regimen prolongs survival and time to metastasis (TTM). (uzh.ch)
- A protocol consisting of combined doxorubicin and dacarbazine is safe in dogs with HSA and prolongs TTM and survival time. (uzh.ch)
- Doxorubicin and dacarbazine chemotherapy was started after a left above-knee amputation. (freethesaurus.com)
- Studies have shown that dacarbazine (DTIC)-doxorubicin (DOX) (D-D) therapy is the most effective treatment. (elsevier.com)
- ABVD (doxorubicin, bleomycin, vinblastine (Vb) and dacarbazine) is the standard regimen inHodgkin's lymphoma (HL).Vincristine (O) is a mitotic spindle agent like Vb. (waocp.org)
- We present updated efficacy and safety analyses in high-risk patient subgroups, defined by Stage IV disease or International Prognostic Score (IPS) of 4-7, enrolled in the ECHELON-1 study that compared brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as first-line therapy after a median follow-up of 37.1 months. (openrepository.com)
DTIC-Dome1
- Dacarbazine gained FDA approval in May 1975 as DTIC-Dome. (wikipedia.org)
Plus dacarbazine10
- Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stag. (oncolink.org)
- Secondary end points included overall survival and objective response rate.Results: A total of 129 patients were randomly assigned to receive selumetinib plus dacarbazine (n = 97) or placebo plus dacarbazine (n = 32). (uni-muenchen.de)
- In the selumetinib plus dacarbazine group, 82 patients (85%) experienced a PFS event, compared with 24 (75%) in the placebo plus dacarbazine group (median, 2.8 v 1.8 months);the hazard ratio for PFS was 0.78 (95% CI, 0.48 to 1.27;two-sided P = .32). (uni-muenchen.de)
- The objective response rate was 3% with selumetinib plus dacarbazine and 0% with placebo plus dacarbazine (two-sided P = .36). (uni-muenchen.de)
- The most frequently reported adverse events (selumetinib plus dacarbazine v placebo plus dacarbazine) were nausea (62% v 19%), rash (57% v 6%), fatigue (44% v 47%), diarrhea (44% v 22%), and peripheral edema (43% v 6%).Conclusion: In patients with metastatic uveal melanoma, the combination of selumetinib plus dacarbazine had a tolerable safety profile but did not significantly improve PFS compared with placebo plus dacarbazine. (uni-muenchen.de)
- Subsequently, 22 patients received L19-IL2 at recommended dose plus dacarbazine. (aacrjournals.org)
- Genasense plus dacarbazine yielded superior results in a large randomized trial," said Dr. (freethesaurus.com)
- Genasense, the company's lead compound, has received "Fast Track" designation from the Food and Drug Administration, and the combination of Genasense plus dacarbazine is currently undergoing a Phase 3 trial in patients with advanced melanoma. (freethesaurus.com)
- Brentuximab Vedotin Plus Dacarbazine or Bendamustine: New Options for Older Patients with Hodgkin Lymphoma? (ashclinicalnews.org)
- At the time of data presentation, 60 patients had been treated: 27 with brentuximab vedotin monotherapy, 22 with brentuximab vedotin plus dacarbazine, and 11 with brentuximab vedotin plus bendamustine. (ashclinicalnews.org)
Malignant Melanoma8
- A Randomized Phase II Trial Comparing Bevacizumab Monotherapy With Dacarbazine (DTIC) in Treatment of Malignant Melanoma, Focusing on Angiogenic Markers and Prevention of Hypertension. (clinicaltrials.gov)
- Dacarbazine is used alone or in combination with other antineoplastic medications to treat metastatic malignant melanoma (a type of skin cancer). (canoe.com)
- Dacarbazine is used in the treatment of various cancers, among them malignant melanoma, Hodgkin lymphoma, sarcoma, and islet cell carcinoma of the pancreas. (selfdecode.com)
- Dacarbazine (DTIC) is an alkylating chemotherapy medication that is used to treat Hodgkin lymphoma and malignant melanoma . (dvohmg.com)
- DTIC (Dacarbazine) is an antineoplastic chemotherapy drug used in the treatment of various cancers, among them malignant melanoma, Hodgkin lymphoma, sarcoma, and islet cell carcinoma of the pancreas. (comprar-medicina.com)
- Dacarbazine is used for treating certain types of cancer, such as skin cancer that has spread (metastatic malignant melanoma). (medsdelta.com)
- To compare the effectiveness of dacarbazine with or without oblimersen (G3139) in treating patients who have advanced malignant melanoma. (isrctn.com)
- O6-Alkylguanine-DNA alkyltransferase (ATase) levels were measured in peripheral blood lymphocytes of 13 patients with advanced malignant melanoma treated with sequential dacarbazine (DTIC) and fotemustine. (openrepository.com)
Versus Dacarbazine1
- NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with advanced NRAS-mutant melanoma who are untreated or have progresse. (esmo.org)
Dosage6
- The recommended dacarbazine dosage will be different for each person, depending on his or her weight, the reason the medicine is being used, and a number of other factors. (emedtv.com)
- What Is the Recommended Dacarbazine Dosage for Treating Melanoma? (emedtv.com)
- The usual recommended dosage of dacarbazine for treating Hodgkin's disease is 150 mg per m 2 daily for 5 days. (emedtv.com)
- Detailed information related to Dacarbazine Injection's uses, composition, dosage, side effects and reviews is listed below. (aviencepharma.com)
- The recommended dosage of Dacarbazine for Injection in the treatment of Hodgkin's disease is 150 mg/square meter body surface/day for 5 days, in combination with other effective drugs. (pfizermedicalinformation.co.nz)
- Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells. (openrepository.com)
ABVD2
- We aimed to investigate whether omission of either bleomycin or dacarbazine, or both, from ABVD reduced the efficacy of this regimen in treatment of Hodgkin's lymphoma. (mdc-berlin.de)
- Interpretation: Dacarbazine cannot be omitted from ABVD without a substantial loss of efficacy. (mdc-berlin.de)
Vial3
- Each vial of sterile lyophilized powder for reconstitution contains dacarbazine 600 mg. (canoe.com)
- Each vial contains 200 mg of dacarbazine (the active ingredient), citric acid monohydrate and mannitol. (pfizermedicalinformation.com.tn)
- Dacarbazine for Injection 200 mg/vial is reconstituted with 19.7 mL of Sterile Water for Injection, USP. (pfizermedicalinformation.co.nz)
Imidazole carboxamide1
- Dacarbazine ( DTIC ), also known as imidazole carboxamide , is a chemotherapy medication used in the treatment of melanoma and Hodgkin's lymphoma . (wikipedia.org)
Intravenous4
- Treatment regimen included orally administered sorafenib and intravenous dacarbazine. (uzh.ch)
- Patients and methods: A total of 859 patients were randomised to receive oral temozolomide at 150 mg/m2/day for seven consecutive days every 2 weeks or dacarbazine, administered as an intravenous infusion at 1000 mg/m2/day on day 1 every 3 weeks. (eur.nl)
- After intravenous administration of Dacarbazine for Injection, the volume of distribution exceeds total body water content suggesting localization in some body tissue, probably the liver. (pfizermedinfo.co.kr)
- Dacarbazine is an intravenous chemotherapy used alone or in combination with other agents for the treatment of certain types of cancer. (nccs.com.sg)
Precautions1
- Before taking Dacarbazine, what precautions must I follow? (nccs.com.sg)
Single agent dacarbazine2
- The extended schedule, escalated dose temozolomide arm showed more toxicity than the standard dose, single agent dacarbazine arm. (eur.nl)
- The standard treatment of advanced melanoma has for many years been single-agent dacarbazine (DTIC). (freethesaurus.com)
Received dacarbazine injection1
- This medication has not been studied in pregnant women, but it is possible that it may also cause birth defects in babies whose mothers received dacarbazine injection during pregnancy. (medlineplus.gov)
Starting dacarbazine treatment1
- It is therefore recommended that any dental work be completed prior to starting dacarbazine treatment. (mydr.com.au)
Hodgkin's1
- When used to treat Hodgkin's lymphoma, dacarbazine is used in combination with other medicines, regardless of the amount used. (emedtv.com)
Ingredients4
- tell your doctor and pharmacist if you are allergic to dacarbazine, any other medications, or any of the ingredients in dacarbazine injection. (medlineplus.gov)
- You must not be given DBLâ„¢ Dacarbazine for Injection if you have an allergy to dacarbazine or any of the ingredients listed at the end of this leaflet. (mydr.com.au)
- The following is a list of possible side-effects that may occur from all constituting ingredients of Dacarbazine Injection. (aviencepharma.com)
- Ingredients Dacarbazine Injection 100 , 200 , 500 and 1000 mg. (medwiseoverseas.in)
Treatment23
- Liver damage may occur more often in people that are receiving other cancer chemotherapy drugs along with dacarbazine treatment. (medlineplus.gov)
- You should not use dacarbazine injection while you are pregnant or plan to become pregnant unless your doctor decides that this is the best treatment for your condition. (medlineplus.gov)
- Probabilistic sensitivity analysis showed that, at a willingness-to-pay (WTP) threshold of ≤$100,000/QALY, dacarbazine was the optimal treatment in ~85% of simulations. (hindawi.com)
- If you are found to be eligible to take part in this study, you will begin treatment with imatinib mesylate, capecitabine, and dacarbazine. (clinicaltrials.gov)
- The fourth, fifth, and sixth were treated with Dacarbazine and Propolis as pre 2h, post 2h, and concomitant treatment. (unboundmedicine.com)
- The in vivo studies revealed that Dacarbazine induced an abnormalities in polychromatic erythrocytes cells (PECs) as increase of cell with micronuclei, while the dual treatment accompanied with improvement of this abnormalities. (unboundmedicine.com)
- Demetri says recent studies have revealed that dacarbazine is much more useful in the treatment of leiomyosarcomas than initially thought. (targetedonc.com)
- Biopsies of skin or superficial lymph node metastases were taken before treatment (baseline), during sorafenib and after dacarbazine therapy and used for transcriptional profiling and validation experiments. (uzh.ch)
- Our data reveal in situ changes in melanoma metastases during treatment with sorafenib and dacarbazine and suggest an additional mechanism of action through immunomodulation. (uzh.ch)
- Cisplatin treatment of melanoma cells resulted in an induction of apoptosis as demonstrated by flow cytometry (accumulation of cells at the subG1 phase of the cell cycle), whereas dacarbazine caused G1/G0 cell cycle arrest, with the effects being improved by pre‑treatment with vitamin D analogs. (spandidos-publications.com)
- Dacarbazine caused transient stimulation of ROS levels and the mitochondrial membrane potential (Δψm) (after 1 or 3 h of treatment, respectively), but the effect was not detectable following prolonged (24 h) incubation with the drug. (spandidos-publications.com)
- however, only a minority of patients with melanoma respond to dacarbazine treatment. (aacrjournals.org)
- Dacarbazine is commonly administered for the treatment of cancers prevalent in reproductive age females. (monash.edu)
- Importantly, diminished ovarian reserve can result in premature ovarian insufficiency and infertility, thus, fertility preservation options should be considered for young female patients prior to dacarbazine treatment. (monash.edu)
- In a retrospective study we analysed the levels of the DNA repair protein O 6 -methylguanine-DNA methyltransferase (MGMT) in melanoma metastases in patients receiving dacarbazine (DTIC) either as a single drug or as part of combination chemotherapy regimens, and related the expression levels to the clinical response to treatment. (ovid.com)
- Before you begin treatment with dacarbazine, you and your doctor should talk about the good dacarbazine will do as well as the risks of using it. (drugster.info)
- July 22, 2015 /PRNewswire/ -- AstraZeneca today announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. (freethesaurus.com)
- Let your healthcare provider know if you experience anything that doesn't seem right during dacarbazine treatment. (emedtv.com)
- Dacarbazine Injection is a medicine that is used for the treatment of Skin Cancer, Cancer Of White Blood Cells, Cancer Of Soft Tissues and other conditions. (aviencepharma.com)
- It is advisable for men undergoing dacarbazine treatment to take contraceptive measures during and for 6 months after termination of therapy. (heethealthcare.co.in)
- Do not drink alcohol while on dacarbazine treatment. (heethealthcare.co.in)
- Patients in the dacarbazine group received a median of 11.5 treatment cycles, those in the monotherapy group had received a median of eight cycles, and the median duration of treatment had not yet been defined for the brentuximab vedotin plus bendamustine cohort. (ashclinicalnews.org)
- Brentuximab vedotin in combination with dacarbazine or bendamustine for frontline treatment of Hodgkin lymphoma in patients aged 60 years and above: interim results of a multi-cohort phase 2 study. (ashclinicalnews.org)
Docetaxel1
- Overall, 1) PNT2258+docetaxel produced a greater than additive effect compared to single agents, 2) PNT2258+dacarbazine was not superior to PNT2258 alone, 3) PNT2258+vemurafenib while highly active, was not superior to vemurafinib therapy alone, and 4) therapeutic PNT2258 exposures have been attained in patients. (aacrjournals.org)
Carboxamide3
- Dacarbazine (5-(3,3-dimethyl-triazeno) imidazole-4-carboxamide), 3 and 6 mM, was toxic to SECs but not to hepatocytes. (aspetjournals.org)
- Besides unchanged dacarbazine, 5-aminoimidazole -4 carboxamide (AIC) is a major metabolite of dacarbazine excreted in the urine. (selfdecode.com)
- Price of Dacarbazine EP Impurity C, VENDOR OF Dacarbazine IMPURITIES, CAS: NA, 5-diazenyl-1H-imidazole-4-carboxamide SUPPLIER, Dacarbazine impurity manufacturer. (synthinkchemicals.com)
Cisplatin5
- This study presents data indicating that nanomolar concentrations of the hormonally active form of vitamin D, 1α,25‑dihydroxyvitamin D3 [1α,25(OH)2D3], its non‑calcemic analogues 20S‑hydroxyvitamin D3 and 21‑hydroxypregnacalciferol, as well as the low‑calcemic synthetic analog calcipotriol, modulate the efficacy of the anticancer drugs cisplatin and dacarbazine. (spandidos-publications.com)
- On the other hand, only 1α,25(OH)2D3 resulted in a minor, but significant effect on the proliferation of melanoma cells treated simultaneously with dacarbazine, but not cisplatin. (spandidos-publications.com)
- Notably, cisplatin (300 µM) exhibited a higher overall antiproliferative activity than dacarbazine. (spandidos-publications.com)
- Finally, cisplatin, dacarbazine and 1α,25(OH)2D3 displayed modulatory effects on the expression of ROS and vitamin D‑associated genes in the melanoma A375 cells. (spandidos-publications.com)
- Patients received cisplatin, vinblastine, and dacarbazine (CVD: cisplatin (20 mg/m 2 ) and vinblastine (1.2 mg/m 2 ) on days 1-4, dacarbazine (800 mg/m 2 ) on day 1 only) concurrently with interleukin 2 (9 MIU/m 2 /day) by continuous i.v. infusion on days 1-4 and IFN-α (5 MU/m 2 /day) on days 1-5, 8, 10, and 12. (aacrjournals.org)
Effects of dacarbazine5
- This study was carried out to investigate the ability of Propolis to ameliorate the adverse cytogenetic effects of Dacarbazine on bone marrow cells. (unboundmedicine.com)
- It could be concluded that there are protective effects of Propolis against the adverse effects of Dacarbazine. (unboundmedicine.com)
- However, investigations of off-target effects of dacarbazine on the ovary are limited. (monash.edu)
- Some of the possible side effects of dacarbazine can include loss of appetite, vomiting, and hair loss. (emedtv.com)
- Some side effects of dacarbazine are potentially serious and should be reported immediately to your healthcare provider. (emedtv.com)
Shown that dacarbazine1
- In conclusion, our results have shown that dacarbazine induced chromosome loss in lymphocytes from patients treated with this drug. (elsevier.com)
Addition of dacarbazine3
- The IFNγ-induced gene signature seemed to be enhanced after addition of dacarbazine to sorafenib. (uzh.ch)
- Serum IFNγ also increased during therapy, particularly after addition of dacarbazine. (uzh.ch)
- While previous studies have indicated that single-agent brentuximab vedotin is safe and effective for these patients, other trials have suggested that its efficacy may be improved by the addition of dacarbazine or bendamustine. (ashclinicalnews.org)
Toxicity9
- To determine the safety, tolerability, dose-limiting toxicity (DLT), and (MTD) of KU-0059436 in combination with dacarbazine. (knowcancer.com)
- Dacarbazine toxicity in murine liver cells: a model of hepatic endothelial injury and glutathione defense. (aspetjournals.org)
- The relative resistance to dacarbazine toxicity seen in hepatocytes is not due to more efficient GSH detoxification, because toxicity was not unmasked in hepatocytes cultures in medium lacking sulfur amino acid precursors of GSH. (aspetjournals.org)
- Hemopoietic depression is the most common toxicity with dacarbazine for injection. (drugster.info)
- This product offered by SynThink is generally used for ANDA , DMF filing, toxicity study of respective drug formulation, Quality Control (QC) of Dacarbazine manufacturing. (synthinkchemicals.com)
- Background: A phase II study of dacarbazine (DTIC), was conducted to determine the response rate, duration of response, toxicity and overall survival of patients with advanced pancreatic islet cell tumors. (elsevier.com)
- Hemopoietic depression is the most common toxicity with Dacarbazine for Injection and involves primarily the leukocytes and platelets, although, anemia may sometimes occur. (pfizermedicalinformation.com.ve)
- Hemopoietic toxicity may warrant temporary suspension or cessation of therapy with Dacarbazine for Injection. (pfizermedicalinformation.com.ve)
- This toxicity has been observed mostly when Dacarbazine for Injection has been administered concomitantly with other anti-neoplastic drugs: however, it has also been reported in some patients treated with Dacarbazine for Injection alone. (pfizermedicalinformation.com.ve)
Dose9
- Dacarbazine alone was ineffective at 80 mg/kg/dose IP. (aacrjournals.org)
- The recommended dose of L19-IL2 in combination with dacarbazine was defined as 22.5 Mio IU. (aacrjournals.org)
- Purpose: To compare the efficacy of an extended schedule escalated dose of temozolomide versus standard dose dacarbazine in a large population of patients with stage IV melanoma. (eur.nl)
- Dacarbazine was used as a control drug and was administered for five consecutive days at a dose of 80 mg/kg. (anavex.com)
- The recommended dose of dacarbazine is based on body weight or body size. (canoe.com)
- The appropriate dose of dacarbazine is often given once daily for 5 or 10 days depending on the dose. (canoe.com)
- The usual recommended dose of dacarbazine for treating melanoma ( skin cancer ) is 2 to 4.5 mg per kg body weight (about 0.09 to 2.04 mg per lb) once a day for 10 days. (emedtv.com)
- The usual recommended dose of dacarbazine based on body surface area is 250 mg per m 2 daily for 5 days. (emedtv.com)
- The average cumulative excretion of unchanged dacarbazine in the urine is 40% of the injected dose in 6 hours. (pfizermedinfo.co.kr)
Hepatic1
- These studies were undertaken to determine the initial cellular target and the role of glutathione detoxification of dacarbazine, a toxin implicated in hepatic veno-occlusive disease. (aspetjournals.org)
Antineoplastic2
- Dacarbazine belongs to a group of medicines known as antineoplastic or cytotoxic agents. (mydr.com.au)
- Description: Dacarbazine is a triazene derivative with antineoplastic activity. (bet-bromodomain.com)
Given dacarbazine2
- You will be given dacarbazine in the chemotherapy day unit or during a stay in hospital. (macmillan.org.uk)
- You should not be given dacarbazine if you are pregnant or intend to become pregnant. (mydr.com.au)
Receive dacarbazine2
- If temozolomide is not available, patients receive dacarbazine intravenously (IV) over 15-60 minutes on day 1. (clinicaltrials.gov)
- 1. Patients in group one will receive dacarbazine once every 3 weeks for up to eight courses in the absence of disease progression. (isrctn.com)
Supplier1
- Dacarbazine, Westren Medicine, Western Drug manufacturer / supplier in China, offering 99.6% High Purity Powder Daunorubicin Hydrochloride (CAS: 23541-50-6) 20mg, High Purity Sertraline HCl Sertraline Hydrochloride 79559-97-0 Tablet and Capsule Garde, Hydrocortisone Sodium Succinate Powder for Injection GMP Factory FDA Approved and so on. (made-in-china.com)
Regimen2
- How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? (semanticscholar.org)
- article{Canellos2004HowII, title={How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? (semanticscholar.org)
Drugs5
- Like many chemotherapy drugs, dacarbazine may have numerous serious side effects, because it interferes with normal cell growth as well as cancer cell growth. (wikipedia.org)
- Dacarbazine is considered to be highly emetogenic , [12] and most patients will be pre-medicated with dexamethasone and antiemetic drugs like 5-HT 3 antagonist (e.g., ondansetron ) and/or NK 1 receptor antagonist (e.g., aprepitant ). (wikipedia.org)
- Dacarbazine can be given in combination with other cancer drugs. (macmillan.org.uk)
- Capecitabine and dacarbazine are drugs that interfere with the growth of cancer cells. (clinicaltrials.gov)
- Drugs used in chemotherapy, such as temozolomide and dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (clinicaltrials.gov)
Intravenously2
- Dacarbazine injection comes as a powder to be mixed with liquid to be injected intravenously (into a vein) over 1 minute or infused intravenously over 15 to 30 minutes by a doctor or nurse in a medical facility. (medlineplus.gov)
- Dacarbazine for Injection, USP is reconstituted and administered intravenously (pH 3 to 4). (pfizermedicalinformation.com.tn)
Abstract1
- abstract = "Background: Dacarbazine is an antitumour drug used with considerable success in the chemotherapy of a number of human neoplasias, particularly advanced disseminated melanoma. (elsevier.com)
Allergic1
- Tell your doctor if you have ever had any unusual or allergic reaction to dacarbazine or any other medicines. (drugster.info)
Treat melanoma4
- Dacarbazine is used to treat melanoma (a type of skin cancer) that has spread to other parts of your body. (medlineplus.gov)
- When dacarbazine is used to treat melanoma, it may be injected once a day for 10 days in a row every 4 weeks or it may be injected once a day for 5 days in a row every 3 weeks. (medlineplus.gov)
- Dacarbazine (DTIC) is a chemotherapy drug used to treat melanoma, Hodgkin lymphoma and soft tissue sarcoma. (macmillan.org.uk)
- Significantly, Dacarbazine, a currently available chemotherapy drug used to treat melanoma and other types of cancer, was found to be completely inactive in the same tests. (anavex.com)
Chemotherapeutic2
- PSM exerts more apoptotic and anti-invasive effects in B16F10 mice melanoma cells as compared to dacarbazine (DTIC), an approved chemotherapeutic drug for treating aggressive melanoma. (rsc.org)
- It is recommended that dacarbazine for injection be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. (drugster.info)
Chemotherapy drug1
- DACARBAZINE (da KAR ba zeen) is a chemotherapy drug. (cvs.com)
Efficacy1
- In a recent phase II, frontline, open-label study, Christopher A. Yasenchak, MD , from the Willamette Valley Cancer Institute and Research Center/US Oncology Research in Springfield, Oregon, and colleagues examined the efficacy and durability of brentuximab vedotin as a single-agent and in combination with dacarbazine or bendamustine in patients with HL ≥60 years old. (ashclinicalnews.org)
Nausea1
- Dacarbazine often causes nausea and vomiting, but it is important to keep using this medication even if you feel ill, unless otherwise directed by your doctor. (canoe.com)
Combination5
- To determine the maximum tolerated doses (MTD) for the combination of imatinib mesylate, capecitabine, and dacarbazine in patients with solid tumors. (clinicaltrials.gov)
- To determine the overall tumor response rate to imatinib mesylate in combination with capecitabine and dacarbazine as first line and second line therapy in advanced metastatic medullary thyroid carcinoma. (clinicaltrials.gov)
- Sorafenib is a multi-kinase inhibitor used alone or in combination with dacarbazine to treat metastasized melanoma. (uzh.ch)
- The first 10 studied patients received escalating doses of L19-IL2 on days 1, 3, and 5 in combination with 1 g/m 2 of dacarbazine on day 1 of a 3-weekly therapy cycle. (aacrjournals.org)
- CD34+ cells were firstly amplified 20-fold Dacarbazine by a combination of TPO SCF and Flt-3 and then they were cultured with HGF and FGF4. (healthweblognews.info)
Phase7
- Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. (harvard.edu)
- Transition probabilities were derived from two Phase III registration trials comparing each BRAF inhibitor against dacarbazine. (hindawi.com)
- This randomized phase II trial studies how well cabozantinib-s-malate works compared with temozolomide or dacarbazine in treating patients with melanoma of the eye (ocular melanoma) that has spread to other parts of the body and cannot be removed by surgery. (clinicaltrials.gov)
- In this phase 3 clinical trial, when Genasense was combined with dacarbazine , the most frequent serious adverse event occurring in more than 5 percent of patients was fever (5. (freethesaurus.com)
- Dacarbazine is not cell cycle-phase specific. (selfdecode.com)
- Phase II trial dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. (elsevier.com)
- Fingerprint Dive into the research topics of 'Phase II trial dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. (elsevier.com)
Impurity1
- Place your order for Dacarbazine EP Impurity C product with CAS: NA. (synthinkchemicals.com)
Alkylating Agent2
- [1] Dacarbazine is in the alkylating agent and purine analog families of medication. (wikipedia.org)
- Dacarbazine is bioactivated in liver by demethylation to "MTIC" and then to diazomethane , which is an alkylating agent. (wikipedia.org)
Melanoma therapy2
- Until the recent approval of ipilimumab and vemurafenib, the melanoma therapy landscape was dominated by two agents, dacarbazine and interleukin-2 ( 4, 5 ). (aacrjournals.org)
- It has been compared to dacarbazine (DTIC), standard melanoma therapy, in a clinical trial with longer follow-up than the ipilimumab trial. (freethesaurus.com)
Belongs to the group1
- Dacarbazine belongs to the group of medicines called alkylating agents. (drugster.info)
Body's2
- Your doctor will order certain tests to check your body's response to dacarbazine. (medlineplus.gov)
- Dacarbazine can cause anemia and reduce the body's ability to fight infections. (dvohmg.com)
Hospira3
- There are also generic versions of dacarbazine available from APP, Bedford, Mayne Pharma (now Hospira ) and Teva . (wikipedia.org)
- NDA 075940 describes DACARBAZINE , which is a drug marketed by Abraxis Pharm , Fresenius Kabi Usa , Hospira , Teva Pharms Usa , and West-ward Pharms Int , and is included in six NDAs. (drugpatentwatch.com)
- hospira inc. received approval authorities for arresting its dacarbazine modified capsules in early january, but the company has reportedly needed considerable time to build oneself up an adequate supply of the drug growing and to reach in thee a comarketing agreement with another large pharmaceutical manufacturer. (victoriangraceart.com)